Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canadian Price Controls May Become Higher Priority For PhRMA

Executive Summary

The impact of international pharmaceutical price controls on the U.S. Medicare debate may be leading PhRMA to step up its international lobbying efforts, particularly in Canada.

You may also be interested in...



Pequot Indians Directed To Stop Supplying FSS Priced Drugs To Employees

The Mashantucket Pequot Tribal Nation should stop providing pharmaceuticals to non-Indian employees of the Foxwoods casino at federal discounted prices, the Indian Health Service told the tribe.

Pequot Indians Directed To Stop Supplying FSS Priced Drugs To Employees

The Mashantucket Pequot Tribal Nation should stop providing pharmaceuticals to non-Indian employees of the Foxwoods casino at federal discounted prices, the Indian Health Service told the tribe.

HHS Will Consult With USTR On Patent Relief Claims From Foreign Countries

HHS will have a formal consulting role in future decisions by the U.S. Trade Representative about claims from foreign governments that patent laws hinder their ability to address a public health emergency.

Related Content

UsernamePublicRestriction

Register

PS035156

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel